张江高科股东张江集团拟减持不超过1%股份；新产业股东红杉聚业拟减持不超过1.8454%股份；大千生 态股东新华发行集团拟减持不超过3%股份；润达医疗股东朱文怡及刘辉拟合计减持不超2.99%股份；豪 威集团控股股东虞仁荣拟大宗交易减持不超1.99%股份；索通发展股东宁聚映山红3号拟减持不超过498 万股；芯碁微装实际控制人、董事长程卓拟减持不超263.48万股公司股份；拓荆科技11个员工持股平台 拟合计减持不超1%股份；塞力医疗股东上海盎泽拟减持不超2%股份；南新制药因涉嫌年报信息披露违 法违规 证监会对公司立案；海南华铁子公司终止36.9亿元算力服务协议 | | | 10月9日A股投资避雷针 | | --- | --- | --- | | 类别 | 公司 张江高科 | 主要内容 张江集团拟减持不超过1%股份 | | | 新产业 大千生态 | 红杉聚业拟减持不超过1.8454%股份 新华发行集团拟减持不超过3%股份 | | | 果麦文化 | 嘉利恩拟减持不超过0.51%股份 | | | 润达医疗 | 股东朱文怡及刘辉拟合计减持不超2.99%股份 | | | 家威集团 | 控股股东虞仁荣拟大宗交易减持不超1.99 ...

Core Viewpoint - Nanjing Pharmaceutical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report disclosure laws, leading to the termination of its major asset restructuring plan [2][4]. Group 1: Regulatory Actions - The CSRC issued a notice of investigation to Nanjing Pharmaceutical due to alleged violations of the Securities Law and the Administrative Penalty Law of the People's Republic of China [2]. - The company announced the termination of its major asset restructuring plan, which was initially intended to involve a cash acquisition without issuing shares or changing control [4]. Group 2: Financial Performance - Since its listing in 2020, Nanjing Pharmaceutical has experienced a continuous decline in revenue and has been in a state of loss since 2021, with a significant loss of 357 million yuan in 2024 [4]. - In the first half of 2025, the company reported revenue of 61.8463 million yuan, a year-on-year decrease of 71.28%, with a net profit of -40.0023 million yuan and a non-recurring net profit of -41.7314 million yuan [4]. Group 3: Market Position - Nanjing Pharmaceutical focuses on the research, production, and sales of antiviral drugs for influenza and other infectious diseases, as well as treatments for major diseases such as malignant tumors, cardiovascular diseases, and diabetes [4]. - As of September 30, 2025, the company's stock price closed at 11.37 yuan per share, with a market capitalization of 3.12 billion yuan [6].

Group 1 - The core point of the article is that Nanjing Pharmaceutical has been investigated by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, leading to the termination of its major asset restructuring plan [2] - Nanjing Pharmaceutical signed an acquisition intention agreement with Future Pharmaceutical on August 26, 2025, which was expected to constitute a major asset restructuring according to relevant regulations [2] - The company has faced continuous revenue decline since its listing in 2020, with a significant loss of 357 million yuan in 2024 and a 71.28% year-on-year revenue drop in the first half of 2025 [3] Group 2 - As of September 30, Nanjing Pharmaceutical's stock price closed at 11.37 yuan per share, with a market capitalization of 3.12 billion yuan [7] - In the first half of 2025, the company reported revenue of 61.8463 million yuan and a net loss of 40.0023 million yuan, with a non-recurring net profit loss of 41.7314 million yuan [3]

格隆汇9月30日丨南新制药(688189.SH)公布，公司近日收到中国证券监督管理委员会(以下简称"中国证 监会")出具的《立案告知书》。因公司涉嫌年报信息披露违法违规，根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 登录新浪财经APP 搜索【信披】查看更多考评等级 ...

南新制药表示，《收购意向协议》签署后，公司积极组织交易各方推进本次交易。公司与交易对方就本 次交易的可行性、交易方案的核心条款等进行了多次论证和磋商，但最终未能就本次交易的核心条款达 成一致意见。为切实维护公司及全体股东利益，经公司审慎研究，并与交易对方友好协商，交易各方一 致同意终止筹划本次交易，并于近日签署了《收购终止协议》。 （文章来源：北京商报） 北京商报讯（记者丁宁）9月30日晚间，南新制药（688189）发布公告称，公司拟终止筹划重大资产重 组事项。 公告显示，此前，南新制药与西藏未来生物医药股份有限公司、许昌未来制药有限责任公司和合肥市未 来药物开发有限公司（以下合称"未来医药"）签署了《收购意向协议》，公司拟以现金方式收购未来医 药持有的标的资产组。 ...

Group 1 - Cambrian's private placement price is set at 1195.02 yuan per share, with a total fundraising amount of 3.985 billion yuan [2] - Bee Assistant plans to raise up to 984 million yuan for projects including cloud terminal computing power center and IoT terminal upgrades [3] - Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange [4] Group 2 - Three squirrels received approval from the China Securities Regulatory Commission for H-share issuance, planning to issue up to 81.5483 million shares [5] - Ruiming Technology has submitted an application for H-share issuance to the Hong Kong Stock Exchange [6] - Binhua Co. plans to invest 1.421 billion yuan in an integrated project for wind and solar energy [7] Group 3 - Sainz's subsidiary plans to invest up to 300 million yuan in the expansion of selection and extraction agents [8] - Hunan YN reported no significant changes in its internal and external operating environment [9] - Electric Power Investment plans to restructure assets and has received a notice from the Shenzhen Stock Exchange to suspend review [10] Group 4 - Guanzhong Ecology is in the planning stage to acquire 51% of Hangzhou Actuary [11] - Aima Technology announced the transfer and suspension of production capacity at its subsidiary in Guangdong [12] - Fosun Pharma's subsidiary received approval for clinical trials of a new drug [13] Group 5 - EVE Battery Investment received a cash dividend of 375 million HKD from its indirect associate, Simoer International [14] - Shanmei International announced a change in its board leadership due to personnel changes [15] - Weiye Co. announced the resignation of its chairman for personal reasons [16] Group 6 - Jiaoda Sinuo's chairman is under detention, and the company has appointed a new acting chairman [17] - Duorui Pharmaceutical is planning a change in control, leading to a stock suspension [18] - ST Zhengping's stock price has seen an abnormal increase, leading to a suspension for investigation [19] Group 7 - Daqian Ecology's shareholder plans to reduce its stake by up to 3% [20] - Rundat Medical's shareholders plan to collectively reduce their stake by up to 2.99% [21] - Seli Medical's shareholder plans to reduce its stake by up to 2% [22] Group 8 - Tianyong Intelligent has been awarded a contract worth 58.8 million yuan for an engine assembly line project [23] - Zhongwu Drone signed a significant contract worth 615 million yuan for drone systems [24]

南新制药(688189.SH)发布公告，此前，公司与西藏未来生物医药股份有限公司、许昌未来制药有限责 任公司和合肥市未来药物开发有限公司(以下合称"未来医药"或"标的公司")签署了《收购意向协议》， 公司拟以现金方式收购未来医药持有的标的资产组。 《收购意向协议》签署后，公司积极组织交易各方推进本次交易。公司与交易对方就本次交易的可行 性、交易方案的核心条款等进行了多次论证和磋商，但最终未能就本次交易的核心条款达成一致意见。 为切实维护公司及全体股东利益，经公司审慎研究，并与交易对方友好协商，交易各方一致同意终止筹 划本次交易，并于近日签署了《收购终止协议》。 ...

南新制药(688189.SH)发布公告，公司近日收到中国证券监督管理委员会(简称"中国证监会")出具的《立 案告知书》(编号：证监立案字0132025024号)。因公司涉嫌年报信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 ...

《收购意向协议》签署后，公司积极组织交易各方推进本次交易。公司与交易对方就本次交易的可行 性、交易方案的核心条款等进行了多次论证和磋商，但最终未能就本次交易的核心条款达成一致意见。 为切实维护公司及全体股东利益，经公司审慎研究，并与交易对方友好协商，交易各方一致同意终止筹 划本次交易，并于近日签署了《收购终止协议》。 南新制药(688189.SH)发布公告，此前，公司与西藏未来生物医药股份有限公司、许昌未来制药有限责 任公司和合肥市未来药物开发有限公司(以下合称"未来医药"或"标的公司")签署了《收购意向协议》， 公司拟以现金方式收购未来医药持有的标的资产组。 ...

智通财经APP讯，南新制药(688189.SH)发布公告，公司近日收到中国证券监督管理委员会(简称"中国证 监会")出具的《立案告知书》(编号：证监立案字0132025024号)。因公司涉嫌年报信息披露违法违规， 根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立 案。 ...